Showing 401 - 420 results of 697 for search '"pharmacy"', query time: 0.07s Refine Results
  1. 401
  2. 402
  3. 403
  4. 404
  5. 405

    Impact of Oxycodone HCl Extended-release Formulary Restrictions on Extended-release Opioid Market Share, Healthcare Resource Utilization and Costs in Commercial and Medicare Plans by Rolin L. Wade, Chi-Chang Chen, Ajita P. De, Jaren C. Howard

    Published 2017-07-01
    “…**Background:** Previous research demonstrated that utilization management (UM) such as prior authorization (PA) or non-formulary (NF) restrictions may reduce pharmacy costs when designed and applied appropriately to certain drug classes. …”
    Get full text
    Article
  6. 406
  7. 407
  8. 408
  9. 409

    Economic Burden of HIV in a Commercially Insured Population in the United States by Cindy Y. Chen, Prina Donga, Alicia K. Campbell, Babafemi Taiwo

    Published 2023-01-01
    “…All-cause costs PPPM for adults with PrEP were $1761 ($1938), with pharmacy costs accounting for 71%. **Conclusions:** Despite advances in ART, patients with newly diagnosed HIV and at-risk patients receiving PrEP continue to incur HRU costs. …”
    Get full text
    Article
  10. 410
  11. 411
  12. 412
  13. 413
  14. 414

    Evaluation of Treatment Patterns and Maintenance Dose Titration Among Patients With Crohn’s Disease Initiating Biologics With 3 Years of Follow-Up by Ruizhi Zhao, Zhijie Ding, Parul Gupta, Laurence Gozalo, Robert Bruette, Victor M. Johnson, Keshia Maughn, Yihang Liu, Sumesh Kachroo

    Published 2023-11-01
    “…**Methods:** This retrospective observational study was conducted using the STATinMED RWD Insights all-payer medical and pharmacy data. Adult patients with at least 1 CD medical claim and at least 1 medical/pharmacy claim for a biologic (adalimumab \[ADA\], certolizumab pegol (CZP), infliximab \[IFX\] and its biosimilar products \[IFX-BS\], ustekinumab \[UST\], and vedolizumab \[VDZ\]) between September 2016 and October 2018 were identified. …”
    Get full text
    Article
  15. 415
  16. 416
  17. 417
  18. 418
  19. 419

    Healthcare Utilization and Costs Among US Adolescents With Alopecia Areata by Markqayne Ray, Elyse Swallow, Kavita Gandhi, Christopher Carley, Vanja Sikirica, Travis Wang, Nicolae Done, James Signorovitch, Arash Mostaghimi

    Published 2022-07-01
    “…Post-index, AT/AU vs controls had more outpatient (14.5 vs 7.1) and dermatologist (3.6 vs 0.3) visits, higher mean plan costs ($9397 vs $2267), including medical ($7480 vs $1780) and pharmacy ($1918 vs $487) costs, and higher OOP costs ($2081 vs $751) (all _P_<.001). …”
    Get full text
    Article
  20. 420